Moderna and Lonza have announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2) and additional Moderna products in the future. Under the terms of the agreement, the companies plan to establish manufacturing suites at Lonza’s facilities in the U.S. and Switzerland for the […]

Alexion has announced it will acquire Portola, a commercial-stage biopharma focused on life-threatening blood-related disorders. Portola’s commercialized medicine, Andexxa  (marketed as Ondexxya in Europe) is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in […]

Pfizer and BioNTech have dosed the first participants in the U.S. and Germany in the Phase 1/2 clinical trial for the BNT162 COVID-19 vaccine program. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. Pfizer and BioNTech’s development […]

TScan Therapeutics has announced it will partner with Novartis to discover and develop novel T cell receptor (TCR) engineered T cell therapies. TCR therapies reprogram a patient’s own T cells to recognize shared cancer targets. The collaboration includes an upfront technology access fee and research funding totaling $30 million, and potential milestone payments contingent on […]

Moderna has been promised up to $483 million from the U.S. Department of Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA) to accelerate development of its mRNA vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2). mRNA-1273 is an mRNA vaccine encoding for a prefusion stabilized form of the Spike (S) protein. […]